Today: 22 March 2026
Subscribe
Browse Category

NYSE:LLY 9 December 2025 - 18 December 2025

Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

Eli Lilly reported positive Phase 3 results for its oral obesity drug orforglipron, showing patients maintained prior weight loss after switching from injectable treatments. Shares rose about 1.75% to $1,060 on Thursday. The company also plans significant price cuts for Mounjaro and Zepbound in Canada, according to a separate report. Lilly said orforglipron’s safety profile matched earlier studies, with mostly mild gastrointestinal side effects.
18 December 2025
··
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly shares rose about 2% to $1,048.47 in early trading Monday after new Phase 3 data showed retatrutide led to nearly 29% weight loss in patients with obesity and knee osteoarthritis. Bank of America trimmed its price target on LLY to $1,268 but kept a “buy” rating. Investors are also watching FDA review timing for orforglipron and ongoing U.S. capacity expansion.
15 December 2025
··
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly shares last closed at $1,027.51 as investors weigh advances in obesity drugs and new manufacturing plans. Retatrutide, the company’s next-generation obesity treatment, showed 28.7% average weight loss in a Phase 3 trial, with more studies due in 2026. Lilly also announced a $6 billion API plant in Alabama. Orforglipron, an oral obesity drug, may see an accelerated FDA review.
14 December 2025
··
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly shares closed at $1,027.51 Friday, up about 3% for the week after late-stage trial data showed its obesity drug retatrutide delivered nearly 29% average weight loss in patients with knee osteoarthritis. The stock rebounded from an early-week dip, outperforming the broader market as investors weighed drug tolerability and future pricing strategy.
13 December 2025
···
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly shares closed at $1,027.51, up 1.8% Friday, and traded near $1,028–$1,029 after hours following a European regulatory panel’s recommendation to expand Mounjaro use to children 10 and older with type 2 diabetes. Volume was about 3.2 million shares. The stock remains 7.6% below its 52-week high set in late November.
12 December 2025
··
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly shares traded near $1,009 Friday after its obesity drug retatrutide showed 28.7% average weight loss in a Phase 3 trial, though with notable discontinuation rates. Reuters reported FDA leaders pushed to speed review of Lilly’s oral GLP-1 drug orforglipron, raising internal concerns. The company is building a $6 billion Alabama plant to boost manufacturing. Analyst price targets remain supportive but vary widely.
12 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly shares closed Thursday near $1,006 after new Phase 3 data showed its obesity drug retatrutide cut body weight by up to 28.7% in patients with knee osteoarthritis. The company announced a $6 billion plant in Alabama and reported Q3 revenue up 54% to $17.6 billion. Mounjaro will be covered by China’s national health insurance from January.
11 December 2025
···
Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market value on November 21, 2025, driven by strong demand for its obesity and diabetes drugs. By December 11, shares traded near $993, with a market cap of about $890 billion, down from the peak. The company’s stock is up over 550% in five years, far outpacing the S&P 500. Investors are now focused on valuation rather than growth.
11 December 2025
··
Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

The Federal Reserve cut rates by 25 basis points, but markets remain volatile as concerns grow over a potential AI spending bubble. Oracle shares fell more than 11% after warning of sharply higher AI costs, dragging down Nvidia, Microsoft, and Amazon. Major banks expect further Fed easing in 2026. Analysts highlight Nvidia, Microsoft, Alphabet, Vertiv, Eli Lilly, General Motors, Goldman Sachs, and Campbell’s as stocks to watch.
11 December 2025
········
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly shares traded near $980 midday Monday, after briefly surpassing $1,050 and becoming the first healthcare firm valued above $1 trillion. Q3 revenue rose 54% to $17.6 billion, fueled by Zepbound and Mounjaro sales topping $10 billion. The company announced a $6 billion Alabama plant for its oral weight-loss drug and completed its Adverum Biotechnologies acquisition. LLY trades at about 49 times trailing earnings, far above big-pharma averages.
10 December 2025
··
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.
10 December 2025
····
Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly will invest over $6 billion to build a pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 permanent and 3,000 construction jobs. The 260-acre facility will produce active ingredients for small-molecule and peptide medicines, including the oral GLP-1 obesity drug orforglipron. Construction is set to begin in 2026 and finish by 2032. State officials call it Alabama’s largest-ever private industrial investment.
10 December 2025
·
Eli Lilly Stock After Hours on December 9, 2025: 9‑Day Slide, $6B Alabama Bet and What to Watch Before the December 10 Open

Eli Lilly Stock After Hours on December 9, 2025: 9‑Day Slide, $6B Alabama Bet and What to Watch Before the December 10 Open

Eli Lilly shares closed down 1.5% at $982.22 on Tuesday, marking a ninth straight daily decline despite announcing a $6 billion manufacturing facility in Huntsville, Alabama. The stock traded flat after hours but rebounded over 3% in early pre-market trading Wednesday, last seen near $1,013. Volume Tuesday reached about 2.5 million shares. The new plant will focus on GLP-1 and small-molecule drug production.
10 December 2025
··
Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly shares traded near $980 Tuesday, down 1.6% but up 57% from their 52-week low, with a market cap around $880 billion after briefly topping $1 trillion in November. The company announced a $6 billion manufacturing facility in Alabama, reported strong Q3 earnings, raised guidance, and posted an 80% risk reduction in a key leukemia trial. Lilly also closed its Adverum acquisition and raised its dividend.
9 December 2025
·
1 … 6 7 8 9 10 … 12

Stock Market Today

  • SATS Ltd Stock Impacted by Slowdown in Asia Aviation Recovery
    March 22, 2026, 11:52 AM EDT. SATS Ltd faces headwinds as the aviation recovery in Asia slows down, affecting its stock performance. The company, a key player in aviation services, is experiencing pressure amid fluctuating air travel demand in the region. Investors are cautious due to the uncertain pace of rebound in passenger volumes. SATS Ltd's financial outlook is challenged by external factors slowing the sector's recovery momentum, leading to market volatility for its shares. This development highlights the difficulties still faced by airlines and related service providers in Asia's post-pandemic landscape.
Go toTop